These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 6293183)

  • 1. Isolation of poliovirus variants resistant to and dependent on arildone.
    Schrom M; Laffin JA; Evans B; McSharry JJ; Caliguiri LA
    Virology; 1982 Oct; 122(2):492-7. PubMed ID: 6293183
    [No Abstract]   [Full Text] [Related]  

  • 2. Isolation and characterization of an arildone-resistant poliovirus 2 mutant with an altered capsid protein VP1.
    Eggers HJ; Rosenwirth B
    Antiviral Res; 1988; 9(1-2):23-35. PubMed ID: 2839108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of arildone and 3-methylquercetin as stabilizers of poliovirus.
    Rombaut B; Vrijsen R; Boeye A
    Antiviral Res; 1985; Suppl 1():67-73. PubMed ID: 3002268
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of arildone on modifications of poliovirus in vitro.
    Caliguiri LA; McSharry JJ; Lawrence GW
    Virology; 1980 Aug; 105(1):86-93. PubMed ID: 6251614
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of uncoating of poliovirus by arildone, a new antiviral drug.
    McSharry JJ; Caliguiri LA; Eggers HJ
    Virology; 1979 Sep; 97(2):307-15. PubMed ID: 224584
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluorescence spectrophotometric study of structural alterations in the capsid of poliovirus.
    Grimmel M; Zibirre R; Koch G
    Arch Virol; 1983; 78(3-4):191-201. PubMed ID: 6318693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro inhibitory effects of dual combinations of picornavirus replication inhibitors.
    Nikolaeva L; Galabov AS
    Acta Virol; 1999 Oct; 43(5):303-11. PubMed ID: 10757231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guanidine-resistant poliovirus mutants produce modified 37-kilodalton proteins.
    Anderson-Sillman K; Bartal S; Tershak DR
    J Virol; 1984 Jun; 50(3):922-8. PubMed ID: 6328023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of susceptibility variants of poliovirus grown in the presence of favipiravir.
    Daikoku T; Mizuguchi M; Obita T; Yokoyama T; Yoshida Y; Takemoto M; Shiraki K
    J Microbiol Immunol Infect; 2018 Oct; 51(5):581-586. PubMed ID: 28709841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus.
    Salvati AL; De Dominicis A; Tait S; Canitano A; Lahm A; Fiore L
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2233-43. PubMed ID: 15155227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Analysis of Antiviral Compounds Against Poliovirus.
    Leyssen P; Franco D; Tijsma A; Lacroix C; De Palma A; Neyts J
    Methods Mol Biol; 2016; 1387():325-38. PubMed ID: 26983743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guanidine-dependent mutants of poliovirus: identification of three classes with different growth requirements.
    Pincus SE; Rohl H; Wimmer E
    Virology; 1987 Mar; 157(1):83-8. PubMed ID: 3029969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant drug targets suppress the emergence of antiviral resistance.
    Tanner EJ; Liu HM; Oberste MS; Pallansch M; Collett MS; Kirkegaard K
    Elife; 2014 Nov; 3():. PubMed ID: 25365453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poliovirus coat protein as the site of guanidine action.
    Korant BD
    Virology; 1977 Aug; 81(1):25-36. PubMed ID: 196400
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.
    Kouiavskaia DV; Dragunsky EM; Liu HM; Oberste MS; Collett MS; Chumakov KM
    Antivir Ther; 2011; 16(7):999-1004. PubMed ID: 22024515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.
    Tijsma A; Thibaut HJ; Spieser SA; De Palma A; Koukni M; Rhoden E; Oberste S; Pürstinger G; Volny-Luraghi A; Martin J; Marchand A; Chaltin P; Neyts J; Leyssen P
    Antiviral Res; 2014 Oct; 110():1-9. PubMed ID: 25043639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein.
    Crotty S; Saleh MC; Gitlin L; Beske O; Andino R
    J Virol; 2004 Apr; 78(7):3378-86. PubMed ID: 15016860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilisation of poliovirus with pirodavir.
    Rombaut B; Andries K; Boeyé A
    Dev Biol Stand; 1996; 87():173-80. PubMed ID: 8854015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral phenoxathiins and their analogs. Study of the structure-activity relationships for antiviral activity and the replacement ability in poliovirus type 3 dependent variants.
    Paget CJ; Dennis EM; Nelson J; DeLong DC
    J Med Chem; 1970 Jul; 13(4):620-3. PubMed ID: 4318071
    [No Abstract]   [Full Text] [Related]  

  • 20. Elucidating mechanisms of thermostabilization of poliovirus by D2O and MgCl2.
    Chen CH; Wu R; Roth LG; Guillot S; Crainic R
    Arch Biochem Biophys; 1997 Jun; 342(1):108-16. PubMed ID: 9185619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.